0001125345-24-000079.txt : 20240408 0001125345-24-000079.hdr.sgml : 20240408 20240408180730 ACCESSION NUMBER: 0001125345-24-000079 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240404 FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peters Jeffrey Stuart CENTRAL INDEX KEY: 0001706903 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36112 FILM NUMBER: 24830676 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MACROGENICS INC CENTRAL INDEX KEY: 0001125345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: Rockville STATE: MD ZIP: 20850 BUSINESS PHONE: 301-251-5172 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 wk-form4_1712614042.xml FORM 4 X0508 4 2024-04-04 0 0001125345 MACROGENICS INC MGNX 0001706903 Peters Jeffrey Stuart 9704 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 0 1 0 0 Senior VP and General Counsel 1 Common Stock 2024-04-04 4 M 0 42500 4.82 A 51395 D Common Stock 2024-04-04 4 S 0 42500 15.07 D 8895 D Common Stock 2024-04-04 4 S 0 147 15.51 D 8748 D Common Stock 2024-04-04 4 S 0 232 16.38 D 8516 D Common Stock 2024-04-04 4 S 0 5351 17.74 D 3165 D Common Stock 2024-04-04 4 S 0 3165 18.22 D 0 D Employee stock option (right to buy) 4.82 2024-04-04 4 M 0 42500 4.82 D 2033-02-15 Common Stock 42500 127500 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023. This transaction was executed in multiple trades at prices ranging from $15.07 to $15.94. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This transaction was executed in multiple trades at prices ranging from $16.01 to $16.58. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This transaction was executed in multiple trades at prices ranging from $17.05 to $17.99. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.84. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 12.5% of the shares underlying the grant become exercisable 6 months after the 2/15/2023 date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. /s/ Lynn M. Cilinski, Attorney-in-fact 2024-04-08